These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 24823863)

  • 1. Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.
    Levy JM; Thompson JC; Griesinger AM; Amani V; Donson AM; Birks DK; Morgan MJ; Mirsky DM; Handler MH; Foreman NK; Thorburn A
    Cancer Discov; 2014 Jul; 4(7):773-80. PubMed ID: 24823863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using BRAF(V600E) as a marker of autophagy dependence in pediatric brain tumors.
    Mulcahy Levy JM; Foreman NK; Thorburn A
    Autophagy; 2014; 10(11):2077-8. PubMed ID: 25484091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors.
    Mulcahy Levy JM; Zahedi S; Griesinger AM; Morin A; Davies KD; Aisner DL; Kleinschmidt-DeMasters BK; Fitzwalter BE; Goodall ML; Thorburn J; Amani V; Donson AM; Birks DK; Mirsky DM; Hankinson TC; Handler MH; Green AL; Vibhakar R; Foreman NK; Thorburn A
    Elife; 2017 Jan; 6():. PubMed ID: 28094001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.
    Goodall ML; Wang T; Martin KR; Kortus MG; Kauffman AL; Trent JM; Gately S; MacKeigan JP
    Autophagy; 2014 Jun; 10(6):1120-36. PubMed ID: 24879157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
    Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
    J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
    Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
    Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Wang W; Kang H; Zhao Y; Min I; Wyrwas B; Moore M; Teng L; Zarnegar R; Jiang X; Fahey TJ
    J Clin Endocrinol Metab; 2017 Feb; 102(2):634-643. PubMed ID: 27754804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autophagy sustains mitochondrial respiration and determines resistance to BRAF
    Díaz-Gago S; Vicente-Gutiérrez J; Ruiz-Rodríguez JM; Calafell J; Álvarez-Álvarez A; Lasa M; Chiloeches A; Baquero P
    Autophagy; 2024 Jun; 20(6):1383-1397. PubMed ID: 38436206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
    Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R
    Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
    Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
    PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
    Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
    Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
    Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
    Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.
    Run L; Wang L; Nong X; Li N; Huang X; Xiao Y
    Endocrine; 2021 Feb; 71(2):418-426. PubMed ID: 32666385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF V600E-dependent role of autophagy in uveal melanoma.
    Zhao Y; Wang W; Min I; Wyrwas B; Moore M; Zarnegar R; Fahey TJ
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):447-455. PubMed ID: 27928645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy.
    Ma ZR; Xiong QW; Cai SZ; Ding LT; Yin CH; Xia HL; Liu W; Dai S; Zhang Y; Zhu ZH; Huang ZJ; Wang Q; Yan XM
    Int Immunopharmacol; 2023 Sep; 122():110617. PubMed ID: 37478666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.
    Peh J; Fan TM; Wycislo KL; Roth HS; Hergenrother PJ
    Mol Cancer Ther; 2016 Aug; 15(8):1859-69. PubMed ID: 27297867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.